Brief Overview on Company’s Performance: Mustang Bio, Inc. (NASDAQ: MBIO)

On 20 Jan 2020, Mustang Bio, Inc. (NASDAQ: MBIO) spotted trading -57.55% off 52-week high price. On the other end, the stock has been noted 72.51% away from the low price over the last 52-weeks. The stock changed -4.20% to recent value of $4.33. The stock transacted 336627 shares during most recent day however it has an average volume of 360.43K shares. The company has 35.91M of outstanding shares and 28.41M shares were floated in the market.

Mustang Bio, Inc (MBIO) recently reported financial results and recent corporate highlights for the third quarter ended September 30, 2019.

Financial Results:

As of September 30, 2019, Mustang’s cash, cash equivalents, short-term investments (certificates of deposit) and restricted cash totaled $73.3M, contrast to $83.1M as of June 30, 2019 and $34.6M as of December 31, 2018, a decrease of $9.8M for the quarter and a raise of $38.7M year-to-date.

Research and development expenses were $7.3M for the third quarter of 2019, contrast to $5.3M for the third quarter of 2018. Non-cash, stock-based compensation expenses included in research and development were $0.7M for third quarter of 2019, contrast to $0.7M for the third quarter of 2018.

Research and development expenses from license acquisitions totaled $0.7M for the third quarter of 2019, contrast to $1.0M for the third quarter of 2018.

General and administrative expenses were $2.0M for the third quarter of 2019, contrast to $1.3M for the third quarter of 2018. Non-cash, stock-based compensation expenses included in general and administrative expenses were $0.4M for the third quarter of 2019, contrast to $0.2M for the third quarter of 2018.

Net loss attributable to ordinary stockholders was $10.2M, or $0.25 per share, for the third quarter of 2019, contrast to $7.5M, or $0.28 per share, for the third quarter of 2018.

The price moved ahead of 10.64% from the mean of 20 days, 28.82% from mean of 50 days SMA and performed 22.45% from mean of 200 days price. Company’s performance for the week was 4.34%, 42.90% for month and YTD performance remained 6.13%.

 

Vivian Moore

Vivian Moore – Health and Biotech I am Vivian Moore, I have done my bachelor’s in English literature, and further on I did my master’s in Medicines. My most preferred genre of writing is health and biotech. I have been writing from the past 6 years about articles, web content, and blogs. In my career and education, I like to play along with work. I have also been a teacher in the past for 2 years. I use to teach business and technical writing in a very famous university. However, most recently I am working as an instructor, designer, and training writer. I enjoy socializing a lot. I am a very big extrovert when it comes to nature. A part of all this I enjoy exploring the world and traveling makes me happy.

Leave a Reply

Your email address will not be published. Required fields are marked *